ImmunoBrain Checkpoint

About:

ImmunoBrain Checkpoint is a biopharmaceutical company.

Website: https://www.ibcheckpoint.com/

Top Investors: National Institutes of Health, Alzheimer's Association, The ALS Association

Description:

ImmunoBrain Checkpoint is a biopharmaceutical company focused on developing a pipeline of novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBC’s novel approach for treatment of neurodegeneration is based on years of innovative, cutting edge scientific discoveries made by Prof. Michal Schwartz (Weizmann Institute of Science, Israel).

Total Funding Amount:

$6.5M

Headquarters Location:

Ness Ziona, HaMerkaz, Israel

Founded Date:

2015-01-01

Contact Email:

info(AT)immunobrain.com

Founders:

Michal Schwartz, Nathan Hevrony

Number of Employees:

1-10

Last Funding Date:

2021-08-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai